Virginia is currently home to 1837 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Richmond, Charlottesville, Norfolk and Fairfax. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT06419634
Recruiting
The purpose of this study is to assess the safety, tolerability, drug levels, drug efficacy and determine the recommended dose of BMS-986497 as a monotherapy, in double combination with Azacitidine and in triple combination with Azacitidine and Venetoclax in participants with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Local Institution - 0009, Fairfax, Virginia
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
Register for Updates
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
NCT06419374
Recruiting
The study will assess the efficacy and safety of pegozafermin administered in participants with compensated cirrhosis due to MASH (biopsy-confirmed fibrosis stage F4 MASH \[previously known as nonalcoholic steatohepatitis, NASH\]).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/04/2025
Locations: 89bio Clinical Study Site, Richmond, Virginia
Conditions: Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Register for Updates
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
NCT06418204
Recruiting
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies with chemotherapy and/or (immune checkpoint inhibitors) ICIs.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Centra Alan B Pearson Regional Cancer Center, Lynchburg, Virginia
Conditions: Breast Carcinoma, Colorectal Carcinoma, Lung Non-Small Cell Carcinoma, Melanoma, Non-Hodgkin Lymphoma
Register for Updates
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06417814
Recruiting
This study will assess the effect of Dato-DXd in combination with osimertinib or Dato-DXd monotherapy versus platinum-based doublet chemotherapy in terms of progression-free survival (PFS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Research Site, Fairfax, Virginia
Conditions: Metastatic Non-small Cell Lung Cancer
Register for Updates
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
NCT06345339
Recruiting
This study will evaluate the efficacy and safety of Armour Thyroid treatment compared with synthetic T4 in subjects who have primary hypothyroidism and are currently stabilized (i.e., in-range thyroid-stimulating hormone \[TSH\]) on synthetic T4 treatment. This study will also therefore evaluate the efficacy and safety of dose conversion from synthetic T4 therapy to Armour Thyroid therapy.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/04/2025
Locations: Virginia Endocrinology Research /ID# 259623, Chesapeake, Virginia
Conditions: Hypothyroidism
Register for Updates
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
NCT06318169
Recruiting
The study will assess the efficacy and safety of 2 dose regimens of pegozafermin for the treatment of liver fibrosis stage 2 or 3 in adult participants with MASH (previously known as nonalcoholic steatohepatitis \[NASH\]).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/04/2025
Locations: 89bio Clinical Study Site, Richmond, Virginia
Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Register for Updates
A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
NCT06311721
Recruiting
The primary objective of this study is to compare the efficacy of ABP 234 with the pembrolizumab reference product (Keytruda®).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
06/04/2025
Locations: Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Wytheville, Virginia
Conditions: Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Register for Updates
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06212999
Recruiting
The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent Phase 3 studies (INCB 54707-301 \[NCT05620823\] or INCB 54707-302 \[NCT05620836\]).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Investigative Site US313, Norfolk, Virginia
Conditions: Hidradenitis Suppurativa (HS)
Register for Updates
Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response
NCT06175000
Recruiting
This randomized phase II trial studies how well obinutuzumab works as maintenance treatment in patients with central nervous system lymphoma who have achieved the disappearance of all signs of cancer in response to treatment (complete response) or a decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment (partial response). Immunotherapy with obinutuzumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to gro... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Primary Central Nervous System Lymphoma
Register for Updates
TRIcvalve biCAVal Valve System for Severe Tricuspid Regurgitation (TRICAV-I)
NCT06137807
Recruiting
The TricValve® Transcatheter Bicaval Valve System is a bicaval transcatheter tricuspid valve replacement system, which includes the TricValve® Transcatheter Bicaval Valve for superior vena cava (SVC) and the TricValve® Transcatheter Bicaval Valve for inferior vena cava (IVC). The TricValve® Transcatheter Bicaval Valves are pre-mounted into the TricValve® Delivery System which is used for percutaneous access and delivery of the TricValve® Transcatheter Bicaval Valve in the vena cava. The system i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: UVA School of Medicine, Charlottesville, Virginia
Conditions: Tricuspid Regurgitation, Tricuspid Valve Disease
Register for Updates
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema
NCT06116916
Recruiting
The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with DME.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Retina Group of Washington, Fairfax, Virginia
Conditions: Diabetic Macular Edema (DME)
Register for Updates
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration
NCT06116890
Recruiting
The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with nAMD.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/04/2025
Locations: Retina Group of Washington, Fairfax, Virginia
Conditions: Neovascular Age-Related Macular Degeneration (nAMD)
Register for Updates